Encephalitis with Autoantibodies against the Glutamate Kainate Receptors GluK2.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
07 2021
Historique:
revised: 03 05 2021
received: 14 01 2021
accepted: 03 05 2021
pubmed: 6 5 2021
medline: 15 9 2021
entrez: 5 5 2021
Statut: ppublish

Résumé

The objective of this study was to report the identification of antibodies against the glutamate kainate receptor subunit 2 (GluK2-abs) in patients with autoimmune encephalitis, and describe the clinical-immunological features and antibody effects. Two sera from 8 patients with similar rat brain immunostaining were used to precipitate the antigen from neuronal cultures. A cell-based assay (CBA) with GluK2-expressing HEK293 cells was used to assess 596 patients with different neurological disorders, and 23 healthy controls. GluK2-ab effects were determined by confocal microscopy in cultured neurons and electrophysiology in GluK2-expressing HEK293 cells. Patients' antibodies precipitated GluK2. GluK2 antibody-specificity was confirmed by CBA, immunoprecipitation, GluK2-immunoabsorption, and GluK2 knockout brain immunohistochemistry. In 2 of 8 samples, antibodies reacted with additional GluK2 epitopes present in GluK1 or GluK3; in both, the reactivity was abrogated after GluK2 immuno-absorption. Six of 8 patients developed acute encephalitis and clinical or magnetic resonance imaging (MRI) features of predominant cerebellar involvement (4 presenting as cerebellitis, which in 2 patients caused obstructive hydrocephalus), and 2 patients had other syndromes (1 with cerebellar symptoms). One of the samples showed mild reactivity with non-kainate receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors [AMPAR] and N-methyl-D-aspartate receptors [NMDAR]) leading to identify 6 additional cases with GluK2-abs among patients with anti-AMPAR (5/71) or anti-NMDAR encephalitis (1/73). GluK2-abs internalized GluK2 in HEK293 cells and neurons; these antibody-effects were reversible in neurons. A significant reduction of GluK2-mediated currents was observed in cells treated with patients' GluK2 serum following the time frame of antibody-mediated GluK2 internalization. GluK2-abs associate with an encephalitis with prominent clinicoradiological cerebellar involvement. The antibody effects are predominantly mediated by internalization of GluK2. ANN NEUROL 2021;90:107-123.

Identifiants

pubmed: 33949707
doi: 10.1002/ana.26098
doi:

Substances chimiques

Autoantibodies 0
Receptors, Kainic Acid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101-117

Subventions

Organisme : "la Caixa" Foundation
Organisme : Agència de Gestió d'Ajuts Universitaris i de Recerca
ID : 2019FI_B100212
Organisme : Basque Government Doctoral Fellowship Programme
ID : PRE_2019_1_0255
Organisme : CIBERER CB15/00010
Organisme : Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
ID : 2017SGR737
Organisme : Edmond J. Safra Center foundation
Organisme : ERA-NET NEURON
Organisme : European Regional Development Fund
ID : BFU2017-83317-P
Organisme : Fundació Cellex
Organisme : Instituto de Salud Carlos III
ID : JR17/00012
Organisme : Instituto de Salud Carlos III
ID : PI20/00197
Organisme : Instituto de Salud Carlos III
ID : PI17/00296
Organisme : Instituto de Salud Carlos III
ID : PI18/00067
Organisme : Instituto de Salud Carlos III
ID : PI18/00486
Organisme : Instituto de Salud Carlos III
ID : Proyecto Integrado de Excelencia 16/00014
Organisme : Instituto de Salud Carlos III
ID : RD16/0008/0014
Organisme : Ministerio de Ciencia e Innovación
ID : Maria de Maeztu MDM-2017-0729
Organisme : Pablove Foundation
ID : 689368
Organisme : Pla estratègic de recerca i innovació en salut (PERIS)
ID : SLT006/17/00362
Organisme : Resident Award Josep Font, Hospital Clinic de Barcelona
Organisme : Torrons Vicenç foundation
ID : PFNR0144

Informations de copyright

© 2021 American Neurological Association.

Références

Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378:840-851.
Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010;62:405-496.
Contractor A, Mulle C, Swanson GT. Kainate receptors coming of age: milestones of two decades of research. Trends Neurosci 2011;34:154-163.
Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-1098.
Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424-434.
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157-165.
Hoftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015;84:2403-2412.
Joubert B, Kerschen P, Zekeridou A, et al. Clinical spectrum of encephalitis associated with antibodies against the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature. JAMA Neurol 2015;72:1163-1169.
Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-5875.
Haselmann H, Mannara F, Werner C, et al. Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction. Neuron 2018;100:91-105.e109.
Christensen JK, Paternain AV, Selak S, et al. A mosaic of functional kainate receptors in hippocampal interneurons. J Neurosci 2004;24:8986-8993.
Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005;128:1764-1777.
Landa J, Guasp M, Petit-Pedrol M, et al. Seizure-related 6 homolog like 2 autoimmunity: neurologic syndrome and antibody effects. Neurol Neuroimmunol Neuroinflamm 2021;8:e916.
Lynch DR, Lawrence JJ, Lenz S, et al. Pharmacological characterization of heterodimeric NMDA receptors composed of NR 1a and 2B subunits: differences with receptors formed from NR 1a and 2A. J Neurochem 1995;64:1462-1468.
Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.
Arino H, Armangue T, Petit-Pedrol M, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016;87:759-765.
Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014;13:575-586.
Planaguma J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015;138:94-109.
Planaguma J, Haselmann H, Mannara F, et al. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. Ann Neurol 2016;80:388-400.
Bettler B, Egebjerg J, Sharma G, et al. Cloning of a putative glutamate receptor: a low affinity kainate-binding subunit. Neuron 1992;8:257-265.
Crisp SJ, Dixon CL, Jacobson L, et al. Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain 2019;142:3398-3410.
Moscato EH, Peng X, Jain A, et al. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;76:108-119.
Egebjerg J, Heinemann SF. Ca2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci U S A 1993;90:755-759.
Burnashev N, Villarroel A, Sakmann B. Dimensions and ion selectivity of recombinant AMPA and kainate receptor channels and their dependence on Q/R site residues. J Physiol 1996;496:165-173.
Sommer B, Kohler M, Sprengel R, Seeburg PH. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991;67:11-19.
Pinheiro PS, Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci 2008;9:423-436.
Lerma J. Kainate receptor physiology. Curr Opin Pharmacol 2006;6:89-97.
Contractor A, Swanson G, Heinemann SF. Kainate receptors are involved in short- and long-term plasticity at mossy fiber synapses in the hippocampus. Neuron 2001;29:209-216.
Schmitz D, Mellor J, Breustedt J, Nicoll RA. Presynaptic kainate receptors impart an associative property to hippocampal mossy fiber long-term potentiation. Nat Neurosci 2003;6:1058-1063.
Lourenco J, Cannich A, Carta M, et al. Synaptic activation of kainate receptors gates presynaptic CB(1) signaling at GABAergic synapses. Nat Neurosci 2010;13:197-204.
Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012;135:1606-1621.
Peng X, Hughes EG, Moscato EH, et al. Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 2015;77:381-398.
Rauschenberger V, von Wardenburg N, Schaefer N, et al. Glycine receptor autoantibodies impair receptor function and induce motor dysfunction. Ann Neurol 2020;88:544-561.
Van Samkar A, Poulsen MNF, Bienfait HP, Van Leeuwen RB. Acute cerebellitis in adults: a case report and review of the literature. BMC Res Notes 2017;10:610.
Emelifeonwu JA, Shetty J, Kaliaperumal C, et al. Acute Cerebellitis in children: a variable clinical entity. J Child Neurol 2018;33:675-684.
Shimokaze T, Kato M, Yoshimura Y, et al. A case of acute cerebellitis accompanied by autoantibodies against glutamate receptor delta2. Brain Dev 2007;29:224-226.
Shiihara T, Kato M, Konno A, et al. Acute cerebellar ataxia and consecutive cerebellitis produced by glutamate receptor delta2 autoantibody. Brain Dev 2007;29:254-256.
Kubota M, Takahashi Y. Steroid-responsive chronic cerebellitis with positive glutamate receptor delta 2 antibody. J Child Neurol 2008;23:228-230.
Berridge G, Menassa DA, Moloney T, et al. Glutamate receptor delta2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome. Neurology 2018;91:e714-e723.
Matsumoto H, Okabe S, Hirakawa-Yamada M, et al. Steroid-responsive focal epilepsy with focal dystonia accompanied by glutamate receptor delta2 antibody. J Neuroimmunol 2012;249:101-104.
Fukuoka T, Takeda H, Ohe Y, et al. Anti-glutamate receptor delta2 antibody-positive migrating focal encephalitis. Clin Neurol Neurosurg 2012;114:1351-1354.
Kurian M, Lalive PH, Dalmau JO, Horvath J. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol 2010;67:118-121.
Armangue T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of Opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016;73:417-424.
Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67-76.
Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276-286.

Auteurs

Jon Landa (J)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Mar Guasp (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Service of Neurology, Hospital Clinic, Barcelona, Spain.

Federico Míguez-Cabello (F)

Neurophysiology Laboratory, Department of Biomedicine, School of Medicine, Neuroscience Institute, University of Barcelona, Barcelona, Spain.

Joana Guimarães (J)

Neurology Department, Centro Hospitalar Universitário São João, Clinical Neurosciences and Mental Health Department, Faculty of Medicine, Porto, Portugal.

Takayasu Mishima (T)

Department of Neurology, Fukuoka University, Fukuoka, Japan.

Fumiko Oda (F)

Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Frauke Zipp (F)

Neurology Department, Focus Program Translational Neurosciences (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Vladimir Krajinovic (V)

University Hospital for Infectious Diseases "Dr. Fran Mihaljevic", Zagreb, Croatia.

Peter Fuhr (P)

Department of Neurology, University Hospital Basel, Basel, Switzerland.

Jerome Honnorat (J)

French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Synatac Team, NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, University Claude Bernard, Villeurbanne, France.

Maarten Titulaer (M)

Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Mateus Simabukuro (M)

Department of Neurology, University of São Paulo Medical School, São Paulo, Brazil.

Jesus Planagumà (J)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Eugenia Martínez-Hernández (E)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Service of Neurology, Hospital Clinic, Barcelona, Spain.

Thais Armangué (T)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Neuroimmunology Unit, Neurology Service, Sant Joan de Déu Children's Hospital, University of Barcelona, Barcelona, Spain.

Albert Saiz (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Service of Neurology, Hospital Clinic, Barcelona, Spain.

Xavier Gasull (X)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Neurophysiology Laboratory, Department of Biomedicine, School of Medicine, Neuroscience Institute, University of Barcelona, Barcelona, Spain.

David Soto (D)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Neurophysiology Laboratory, Department of Biomedicine, School of Medicine, Neuroscience Institute, University of Barcelona, Barcelona, Spain.

Francesc Graus (F)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Lidia Sabater (L)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Josep Dalmau (J)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Service of Neurology, Hospital Clinic, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Catalan Institute for Research and Advanced Studies (ICREA), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH